

### AZD-1222

**S**

#### **Leukocytoclastic vasculitis: case report**

A 68-year-old woman developed leukocytoclastic vasculitis following vaccination with AZD-1222 [*route and dosage not stated*].

The woman presented with asymptomatic erythematous to purpuric non-blanching macules on both lower extremities for 2 days. Anamnesis revealed that she had received first dose of AZD-1222 [ChAdOx1 nCoV-19; Astrazeneca] as vaccination against COVID-19 at 7 days prior to current presentation. Subsequent laboratory findings showed decreased C3 and C4 levels. Histopathological examination revealed interstitial and perivascular inflammatory infiltration with lymphocytes, eosinophils, neutrophils and with extravasation of a few erythrocytes. Investigational findings were consistent with leukocytoclastic vasculitis secondary to AZD-1222.

The woman was treated with methylprednisolone and colchicine. Thereafter, her lesions resolved. Subsequently, she received second dose of AZD-1222 which led to slight recurrence of lesions. The lesions resolved spontaneously in a few days.

Jin WJ, et al. Leukocytoclastic vasculitis after coronavirus disease 2019 vaccination. *Journal of Dermatology* 49: e34-e35, No. 1, Jan 2022. Available from: URL: <http://doi.org/10.1111/1346-8138.16212>

803634630